ABT vs BSX — Key Metrics
| Metric | ABT (ABBOTT LABORATORIES) | BSX (BOSTON SCIENTIFIC CORP) |
|---|---|---|
| Price | 104.48 | 43.64 |
| Market Cap | 180.95 Billion | 63.26 Billion |
| P/E (TTM) | 38.84 | 18.34 |
| P/B (Quarterly) | 3.875 | 2.506 |
| P/S (TTM) | 3.75 | 3.0 |
| Net Profit Margin (TTM) | 9.7 | 16.6 |
| Gross Margin (TTM) | 56.9 | 69.1 |
| ROE (TTM) | 9.0 | 13.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Underperform
Greatly Outperform
Recommendation Summary
Stock ABT is projected to underperform the market, stock BSX is projected to greatly outperform the market. Upfront Recommendation: BSX.
Financial Metrics
| ABT | Metrics | BSX |
|---|---|---|
| $104.48 | Price | $43.64 |
| — | Market Capitalization | — |
| 38.84 | Price to Earnings Ratio | 18.34 |
| 3.75 | Price to Sales | 3.0 |
| 26.78 | Price to FCF Ratio | 18.99 |
| 6.59 | Price to Gross Profit | 4.34 |
| 54.6 | Price to R&D | 29.3 |
| 7.7 | Price to Current Assets | 7.75 |
ABT vs BSX at a glance
Abbott Laboratories (ABT) and Boston Scientific Corp (BSX) are both Medical Devices companies in the Healthcare sector. ABT is the larger, at $181.0 billion in market value against $63.3 billion for BSX, about 2.9 times the size.
On trailing-twelve-month figures, ABT trades at 38.8 times trailing earnings and BSX at 18.3; net profit margins are 9.7% and 16.6%.
The Upfront Investment model currently rates ABT Underperform and BSX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.